一、基本情况
| 姓名 | 性别 | 出生年月 |
招生专业 | |||
| 王玉琢 | 男 | ** | ||||
|
专业技术职务 |
行政职务 | |||||
| 教授 | 外科学（泌尿外） | |||||
|
招生类型 |
所在单位 | |||||
| 科学学位（博）\科学学位（硕） | 天津医科大学第二 医院 | |||||
| 最后学历及学位 | ||||||
| 毕业院校 | 毕业时间 | 所学专业 | 所获学位 | |||
| 中国,香港大学 | 1997 | 肿瘤生物学 | 博士 | |||
| | 科学研究主要方向 | |||||
| ywang@bccrc.ca | 肿瘤个体化治疗研究/前列腺癌发病机制 | |||||
二、目前承担科研课题情况
| 项目名称（级别最高 3-5 项）、项目 编号 | 项目来源 | 本人排名 | 本人可支配 经费（万） | 项目起止时间 |
| 1、患者来源基因型确定的下一代前列 腺癌异种移植模型用于抗癌药物的研 发 | CIHR 加拿大健康研究所 |
1 |
75（加元） |
2012.4-2015.3 |
| 2、 Identification of miRNAs and their specific gene targets that are critical for prostate cancer metastases |
CIHR 加拿大健康研究所 |
1 |
77.5（加 元） |
2012.01-2016. 12 |
| 3 Identification of genes involved in development and progression of neuroendocrine prostate cancer |
Prostate cancer Canada |
1 |
20 （加 元） |
2014.07-2016. 06 |
| 4. BIRC6 Anti-Apoptosis Targeting | Terry Fox Research Institute | 1 | 70 （加元） | 2011.09-2016. 08 |
三、发表论文论著情况
| 题目 | 刊物或出版社 | 本人排名 | 发表时间 | 收录情况 （SCI、EI） |
| GATA2 as a potential metastasis-driving gene in prostate cancer. | Oncotarget | 通讯作者 | 2014 | SCI |
| Prostate cancer metastasis-driving genes: hurdles and potential approaches in their identification | Asian Journal of Andrology | 通讯作者 | 2014 | SCI |
| Next generation patient-derived prostate cancer xenograft models. | Asian Journal of Andrology | 通讯作者 | 2014 | SCI |
| High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development | Cancer Research | 通讯作者 | 2014 | SCI |
| Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model | Molecular Oncology | 通讯作者 | 2014 | SCI |
| Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer . | Oncotarget | Last Second | 2014 | SCI |
| REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. | Nucleic Acids Research | Last Fourth | 2014 | SCI |
| The non-coding transcriptome as a dynamic regulator of cancer metastasis | Cancer and Metastasis Reviews | Last Second | 2014 | SCI |
| Genistein vs. ICI 182, 780: an Ally or Enemy in Metastatic Progression of Prostate Cancer. | The Prostate | 通讯作者 | 2013 | SCI |
| Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? | J Pathology | 通讯作者 | 2013 | SCI |
| ERBB4 is a novel driver of metastasis in Ewing sarcoma. | EMBO Mol Med | Last Third | 2013 | SCI |
| Expression and Function of the Progesterone Receptor in Human Prostate Stroma Provide Novel Insights to Cell Proliferation Control. | J Clin Endocrinol Metab | Last Third | 2013 | SCI |
| Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. | International Journal of Molecular Sciences | Last Third | 2013 | SCI |
| Lessons from in vivo models of castration-resistant prostate cancer. | Curr Opin Urol | 通讯作者 | 2013 | SCI |
| BIRC6 Protein, an Inhibitor of Apoptosis: Role in Survival of Human Prostate Cancer Cells. | PLoS ONE | 通讯作者 | 2013 | SCI |
| Elevated expression of BIRC6 protein in non-small cell lung cancers is associated with cancer recurrence and chemoresistance | J Thorac Oncol | 通讯作者 | 2013 | SCI |
| Deletion of leucine zipper tumor suppressor 2 (lzts2) increases susceptibility to tumor development. | J Biol Chem. | Last Second | 2013 | SCI |
| From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer | J Pathology | No.12 | 2013 | SCI |
四、主要业绩
